![]() |
市場調查報告書
商品編碼
2065173
機器人復健系統市場預測至2034年—按產品類型、治療領域、移動性、技術、應用、最終用戶和地區分類的全球分析Robotic Rehabilitation Systems Market Forecasts to 2034 - Global Analysis By Product Type, Therapy Area, Mobility Type, Technology, Application, End User and By Geography |
||||||
根據 Stratistics MRC 的數據,全球機器人復健系統市場預計在 2026 年達到 21 億美元,到 2034 年達到 78 億美元,預測期內複合年成長率為 17.9%。
機器人復健系統涵蓋了多種電子機械和人工智慧驅動的設備,包括外骨骼、治療機器人和穿戴式輔助系統。這些設備旨在為神經系統疾病、整形外科損傷或進行性肌肉骨骼疾病患者提供標準化、高重複性的運動療法。透過引導患肢進行精確的治療性運動,並持續收集動態性能數據,這些系統使治療師能夠客觀地評估功能恢復的進展,並制定個人化的復健方案。
中風發生率上升和神經復健需求增加
中風仍然是全球長期殘疾的主要原因之一,每年新增病例數百萬,需要進行強化神經復健以恢復運動功能、行走能力和生活自理能力。機器人復健系統提供高強度、針對特定任務的重複性運動療法,神經可塑性研究已證實,這種療法對中風後功能恢復最為有效。這種療法無法透過傳統的手工物理治療大規模、永續地實施。隨著世界人口老化,中風和神經退化性疾病的發生率不斷上升。同時,隨著公共衛生領域對復健效果的投入不斷增加,資金正被投入到能夠比傳統方法更有效率、更穩定地提供實證強化治療的技術中。
機器人輔助治療療程實施成本高且保險報銷有差異
實施機器人復健系統需要大量的初始投入,先進的外骨骼平台價格從數十萬美元到超過一百萬美元不等。這使得大多數地區復健中心和長期照護機構難以負擔。此外,大多數醫療保險計劃中機器人輔助治療的每次療程報銷標準尚不明確,保險公司通常要求其療效優於傳統療法,才會批准擴大報銷範圍。主要市場缺乏機器人復健的標準化報銷代碼,造成了財務上的不確定性,阻礙了投資,並延緩了大學醫院和大規模專科復健醫院以外的機構採用該技術。
一個利用機器人和遊戲化技術進行居家復健的治療互動平台。
在居家復健領域,輕便便攜的外骨骼和機器人輔助設備正成為重要的商業性前沿,這些設備專為無人監管的使用而設計,極大地拓展了目標市場,使其不再局限於醫療機構。這些設備與遊戲化的復健互動平台和遠距治療師監控功能相結合,使患者能夠在兩次住院之間繼續進行高強度康復,從而改善治療效果並減輕醫療機構的負擔。虛擬實境環境與機器人復健硬體的融合,創造了沉浸式且引人入勝的治療體驗,提高了患者的積極性和治療依從性,尤其對於兒童和神經系統疾病患者群體而言,持續參與是治療成功的關鍵因素。
缺乏臨床證據和對引入治療師的抵制
儘管支持機器人復健有效性的同儕審查文獻日益增多,但高品質隨機對照試驗提供的證據範圍仍然有限,不足以證明其在某些適應症和患者亞群中明顯優於強化傳統物理治療。一些復健臨床醫生擔心,機器人系統可能更容易受到熟練的手法治療的影響,這限制了患者的反應能力,尤其是在嚴重痙攣或特定運動功能障礙的患者中。物理治療專業組織謹慎地建議將機器人復健視為輔助療法而非替代療法,這限制了其取代傳統、勞動密集型療法的可能性,並抑制了在康復人員已相當成熟的市場中商業性成長的預期。
新冠疫情對機器人復健造成了嚴重的短期衝擊,包括復健中心的關閉和縮減,以及原計劃用於術後復健的整形外科手術的延期。然而,這場危機凸顯了遠端復健監測的價值,並加速了居家機器人平台的發展。疫情過後,由於手術延長和中風治療延遲,復健需求不斷累積,導致需要強化復健的患者數量大幅增加。這種需求的累積使得復健需求居高不下,人們重新燃起了對能夠有效提升醫療系統復健處理能力的科技主導方法的興趣。
在預測期內,外骨骼機器人領域預計將佔據最大的市場佔有率。
預計在預測期內,外骨骼機器人領域將佔據最大的市場佔有率,這主要得益於強力的臨床證據支持外骨骼輔助步態訓練在中風和脊髓損傷復健中的應用。外骨骼能夠達到可重複且高強度的步態模式訓練,加速患者功能性行走能力的恢復,同時減輕復健治療師的體力負擔。輕量化材料、電池能量密度和自適應控制演算法的不斷進步,正在擴大外骨骼平台的臨床應用範圍,使其能夠適應不同病情嚴重程度和復健環境。
預計在預測期內,人工智慧復健系統領域將呈現最高的複合年成長率。
在預測期內,xx細分市場預計將呈現最高的成長率。這反映出市場對智慧治療適應平台的需求日益成長,這些平台能夠根據患者的個別表現數據,即時個人化地調整操作參數、強度增加和療程配置。醫療服務提供者越來越關注利用人工智慧系統,這些系統能夠使用客觀的動態指標來量化復健進展,從而實現數據驅動的治療最佳化和治療結果預測。透過人工智慧分析展示可衡量的功能改善軌跡,能夠為獲得保險報銷和打造差異化的臨床項目提供強力的價值提案。
在預測期內,北美預計將佔據最大的市場佔有率。這主要得益於該地區中風和整形外科手術的高發生率、完善的復健醫院基礎設施,以及主要私人保險公司積極考慮為機器人輔助治療的適應症提供保險報銷。美國在區域應用方面處於領先地位,其主要復健醫院網路已將外骨骼和治療機器人納入其治療方案,作為臨床差異化優勢。大學附屬醫療中心的研究計畫推動了臨床證據的積累,進一步鞏固了北美在機器人復健技術應用方面的主導地位。
在預測期內,亞太地區預計將呈現最高的複合年成長率。這主要歸因於日本、中國和韓國人口的快速老化,推動了對神經和肌肉骨骼復健的需求成長。尤其是在日本和中國,政府支持的研究計畫和對製造業的投資正在加速創新和商業化進程,國內機器人產業也正在開發專用的復健平台。全部區域復健醫院網路的不斷擴展以及中產階級在先進復健技術方面醫療費用支出的不斷增加,為機器人系統的應用創造了有利的市場環境。
According to Stratistics MRC, the Global Robotic Rehabilitation Systems Market is accounted for $2.1 billion in 2026 and is expected to reach $7.8 billion by 2034, growing at a CAGR of 17.9% during the forecast period. Robotic Rehabilitation Systems encompass a broad spectrum of electromechanical and AI-powered devices including exoskeletons, therapeutic robots, and wearable assistive systems designed to deliver standardized, high-repetition movement therapy for patients recovering from neurological events, orthopedic injuries, or progressive musculoskeletal conditions. These systems guide affected limbs through precise therapeutic movement patterns while continuously capturing biomechanical performance data, enabling therapists to objectively assess functional progress and personalize rehabilitation protocols.
Rising stroke incidence and growing demand for neurological rehabilitation
Stroke remains among the leading causes of long-term disability globally, with millions of new cases annually requiring intensive neurorehabilitation to recover motor, gait, and functional independence. Robotic rehabilitation systems deliver the high-intensity, task-specific repetitive movement therapy that neuroplasticity research demonstrates is most effective for post-stroke functional recovery a therapy volume that manual physical therapy cannot sustainably provide at scale. Aging global populations amplify stroke and neurodegenerative disease incidence, while expanding public health investment in rehabilitation outcomes is directing capital toward technologies that can deliver evidence-based intensive therapy more efficiently and consistently than traditional approaches.
High acquisition costs and reimbursement gaps for robotic therapy sessions
Robotic rehabilitation systems carry substantial capital acquisition costs ranging from hundreds of thousands to over a million dollars for advanced exoskeleton platforms, placing procurement decisions beyond the financial reach of most community rehabilitation centers and long-term care facilities. Per-session reimbursement rates for robotic-assisted therapy remain poorly defined in most healthcare systems, with payors frequently requiring demonstration of superior outcomes over conventional therapy before extending coverage approvals. The absence of standardized reimbursement codes for robotic rehabilitation in major markets creates financial uncertainty that deters capital investment and slows adoption outside academic medical centers and large specialty rehabilitation hospitals.
Home rehabilitation robotics and gamified therapy engagement platforms
A significant commercial frontier is emerging in lightweight, portable exoskeleton and robotic assist devices designed for unsupervised use in home rehabilitation settings, dramatically expanding the addressable market beyond institutional buyers. These devices, paired with gamified therapy engagement platforms and remote therapist monitoring capabilities, enable patients to maintain high-intensity rehabilitation between clinical visits improving outcomes while reducing healthcare facility burden. The integration of virtual reality environments with robotic rehabilitation hardware creates immersive, engaging therapy experiences that improve patient motivation and adherence, particularly for pediatric and neurological patient populations where sustained participation is a critical success determinant.
Clinical evidence gaps and therapist adoption resistance
Despite growing peer-reviewed literature supporting robotic rehabilitation efficacy, the breadth of high-quality randomized controlled trial evidence demonstrating clear superiority over intensive conventional physical therapy remains incomplete across several indications and patient subgroups. Some rehabilitation clinicians express concerns that robotic systems constrain the adaptive, patient-responsive nature of skilled manual therapy, particularly for patients with high spasticity or unusual movement dysfunction. Physical therapy professional associations' cautious endorsement of robotic rehabilitation as a supplementary rather than replacement therapy modality limits the displacement of traditional labor-intensive approaches and tempers commercial growth expectations in markets with established rehabilitation workforces.
The COVID-19 pandemic created significant short-term disruption for robotic rehabilitation, as rehabilitation centers closed or reduced capacity and elective orthopedic surgeries generating post-operative rehabilitation demand were postponed. However, the crisis highlighted the value of remote rehabilitation monitoring and accelerated development of home-use robotic platforms. Post-pandemic, pent-up rehabilitation demand from deferred surgeries and pandemic-related stroke care delays created substantial patient volumes requiring intensive rehabilitation. This backlog has sustained elevated demand and renewed health system interest in technology-driven approaches to increasing rehabilitation throughput efficiently.
The Exoskeleton Robots segment is expected to be the largest during the forecast period
The exoskeleton robots segment is expected to account for the largest market share during the forecast period, driven by strong clinical evidence supporting exoskeleton-assisted gait training in stroke and spinal cord injury rehabilitation. Exoskeletons enable reproducible, intensive gait pattern training that accelerates functional ambulation recovery while reducing physical strain on rehabilitation therapists. Continuing advances in lightweight materials, battery energy density, and adaptive control algorithms are expanding the clinical applicability of exoskeleton platforms across patient severity levels and rehabilitation settings.
The AI-Enabled Rehabilitation Systems segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the xx segment is predicted to witness the highest growth rate, reflecting growing demand for intelligent therapy adaptation platforms that personalize movement parameters, intensity progression, and session structure in real time based on individual patient performance data. Health systems are increasingly attracted to AI-powered systems capable of quantifying rehabilitation progress with objective biomechanical metrics, enabling data-driven therapy optimization and outcome prediction. The ability to demonstrate measurable functional improvement trajectories through AI analytics creates compelling value propositions for reimbursement justification and clinical program differentiation.
During the forecast period, the North America region is expected to hold the largest market share, driven by high stroke and orthopedic surgery incidence, strong rehabilitation hospital infrastructure, and active reimbursement exploration by major commercial insurers for robotic-assisted therapy indications. The United States leads regional adoption, with major rehabilitation hospital networks incorporating exoskeleton and therapeutic robot programs as clinical differentiators. Academic medical center research programs driving clinical evidence generation further reinforce North America's leadership position in robotic rehabilitation technology adoption.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by rapidly aging populations in Japan, China, and South Korea creating expanding neurological and musculoskeletal rehabilitation demand. Government-backed research programs and manufacturing investments particularly in Japan and China where domestic robotics industries are advancing rehabilitation-specific platforms are accelerating both innovation and commercialization. Expanding rehabilitation hospital networks across the region and growing middle-class health expenditure on advanced rehabilitation technologies create a receptive market environment for robotic system adoption.
Key players in the market
Some of the key players in Robotic Rehabilitation Systems Market include Ekso Bionics, Lifeward, CYBERDYNE Inc., Hocoma, Tyromotion GmbH, Fourier Intelligence, Myomo Inc., BIONIK Laboratories, Wandercraft, Rex Bionics Ltd., AlterG, Inc., Ottobock SE & Co. KGaA, Kinova Inc., Rehab-Robotics Company Limited, and Motorika Medical Ltd.
In March 2026, CYBERDYNE Inc. received expanded regulatory clearance for its HAL robotic exoskeleton platform in additional neurological rehabilitation indications, enabling broader clinical deployment across stroke and progressive neurodegenerative disease rehabilitation programs at certified medical institutions internationally.
In February 2026, Hocoma launched an enhanced AI-powered therapy optimization module for its Lokomat robotic gait rehabilitation platform, enabling individualized therapy parameter adaptation based on real-time biomechanical performance data analysis and providing therapists with comprehensive outcome tracking dashboards for clinical program management.
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.